For every 1000 patients with recent hospitalization with worsening HF, allocation to an SGLT-2 inhibitor was estimated to prevent 204 HF hospitalizations and 17 cardiovascular deaths in the course of a year. The gene discussed is SLC5A2; the disease is hydrops fetalis.